Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

12.08 +0.44 (+3.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 336,267
Open 11.82
Bid (Size) 11.32 (2)
Ask (Size) 12.83 (1)
Prev. Close 11.64
Today's Range 11.61 - 12.25
52wk Range 8.210 - 17.70
Shares Outstanding 57,771,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines. 
Via Stocktwits
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire

Performance

YTD
-18.3%
-18.3%
1 Month
-6.2%
-6.2%
3 Month
-13.4%
-13.4%
6 Month
-14.9%
-14.9%
1 Year
+38.7%
+38.7%

More News

Read More
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
Via Stocktwits
Exposures Product Safety
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Via Benzinga
Topics Earnings
Exposures Financial
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2025
Via Benzinga
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Zymeworks in Focus for Insider Activity: Catalysts Ahead
Via MarketBeat
Exposures Product Safety
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
From Zymeworks Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 12.08
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 06/03/25 04:00 PM ET
What is the market capitalization of Zymeworks Inc. - Common Stock?
The market capitalization of Zymeworks Inc. - Common Stock is 697.88M
How many shares of Zymeworks Inc. - Common Stock are outstanding?
Zymeworks Inc. - Common Stock has 698M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.